Twist Bioscience Corporation (NASDAQ:TWST) on Monday posted first-quarter 2026 results of a loss of 50 cents per share, in line with Wall Street expectations. Revenue reached $103.70 million, up 17% year over year, exceeding consensus of $102.72 million and management guidance of $100 million to $101 million. Adjusted EBITDA loss for the quarter was $13.4 […]
